Q-omics provides the consensus-scored C2orf16 profile across patient tissues and cancer cell-line models. C2orf16 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, C2orf16 is differentially expressed in 12, with the highest sampling consensus in LUAD. Additionally, C2orf16 RNA expression shows 19,262 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight BLCA, LUAD, and ACC as cancer lineages where C2orf16 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for C2orf16 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes C2orf16 survival associations across molecular data types. C2orf16 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (10). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible C2orf16 RNA expression–survival associations across cancer types. High C2orf16 expression shows unfavorable associations in BLCA, CESC, KIRP, OV and CHOL, but favorable associations in MESO. The BLCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify BLCA as the clearest survival context for C2orf16 RNA expression.
This table summarizes C2orf16 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in LUAD for RNA.
This table ranks reproducible tumor–normal expression differences for C2orf16. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. C2orf16 shows lower tumor expression in KICH and higher tumor expression in LUAD, HNSC, LIHC, LUSC and THCA. The LUAD box plot shows higher C2orf16 RNA expression in tumor versus normal tissue (log2 FC = +0.658, t-test p < 0.001).
This table shows molecular features associated with C2orf16 in patient tissues and cancer cell lines. In patient samples, C2orf16 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, C2orf16 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and SOFT_TISSUE.
